Want to see AU:ADR full AI Analyst Report?
Top Page
Adherium Ltd.
(Sydney:ADR)
Select Model
Select Model
Rating:40Underperform
Price Target:
AU$0.06
▼(-40.00% Downside)
Action:Downgraded
Date:10/24/26
Overall score reflects a high-risk profile driven primarily by weak financial performance (large ongoing losses, sustained cash burn, and negative equity). Technicals further weigh on the score given bearish momentum and trading below key moving averages, while valuation is difficult to justify on earnings due to a negative P/E and no provided dividend yield.
Positive Factors
Revenue Rebound
The sharp 2026 revenue rebound indicates that Adherium’s connected respiratory-health offering can regain commercial traction after weaker periods. If maintained, stronger sales would expand the base over which fixed costs are absorbed and provide a foundation for improving operating performance.
Negative Factors
Severe Unprofitability
The scale of operating and net losses relative to revenue indicates that the cost base is not yet scaling with commercial activity. Unless expense intensity improves materially, even a revenue rebound may not translate into sustainable earnings or reduce the company’s ongoing need for capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Rebound
The sharp 2026 revenue rebound indicates that Adherium’s connected respiratory-health offering can regain commercial traction after weaker periods. If maintained, stronger sales would expand the base over which fixed costs are absorbed and provide a foundation for improving operating performance.
Read all positive factors
Adherium Ltd. (ADR) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$3.68M
Dividend YieldN/A
Average Volume (3M)30.87K
Price to Earnings (P/E)―
Beta (1Y)1.26
Revenue Growth157.02%
EPS Growth69.43%
CountryAU
Employees40
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.40
Shares Outstanding54,887,672
10 Day Avg. Volume60,567
30 Day Avg. Volume30,874
Financial Highlights & Ratios
PEG Ratio0.67
Price to Book (P/B)-731.83
Price to Sales (P/S)449.48
P/FCF Ratio-63.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-9.73
Revenue Forecast (FY)AU$9.01M
Adherium Ltd. Business Overview & Revenue Model
Company Description
Adherium Limited specializes in developing, manufacturing, and providing advanced digital health solutions. The company's core mission is to enhance medication adherence for individuals managing chronic conditions in key international markets, spa...
How the Company Makes Money
null...
Adherium Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
15
Very Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.10M | 817.24K | 840.98K | 3.19M | 529.00K |
| Gross Profit | 1.22M | 111.37K | 267.70K | 1.69M | -690.00K |
| EBITDA | -14.36M | -12.44M | -11.56M | -11.50M | -12.65M |
| Net Income | -14.16M | -12.68M | -10.22M | -9.86M | -10.04M |
Balance Sheet | |||||
| Total Assets | 4.56M | 3.52M | 9.89M | 12.68M | 8.53M |
| Cash, Cash Equivalents and Short-Term Investments | 1.42M | 43.26K | 6.20M | 9.08M | 5.28M |
| Total Debt | 2.40M | 3.12M | 93.20K | 44.00K | 85.00K |
| Total Liabilities | 5.85M | 8.28M | 3.41M | 3.47M | 3.00M |
| Stockholders Equity | -1.29M | -4.76M | 6.48M | 9.21M | 5.54M |
Cash Flow | |||||
| Free Cash Flow | -14.87M | -10.03M | -10.61M | -9.32M | -9.89M |
| Operating Cash Flow | -14.83M | -9.98M | -10.61M | -9.28M | -9.61M |
| Investing Cash Flow | -39.00K | -48.19K | -37.00 | -41.00K | -279.00K |
| Financing Cash Flow | 16.32M | 3.87M | 7.73M | 13.07M | 0.00 |
Adherium Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | AU$148.48M | 64.71 | 2.53% | ― | 26.61% | 41.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$14.31M | -5.88 | -416.53% | ― | 113.42% | 29.17% | |
45 Neutral | AU$22.74M | -1.22 | -58.13% | ― | 2.08% | -195.31% | |
44 Neutral | AU$8.29M | -0.45 | -614.15% | ― | -46.09% | 70.70% | |
40 Underperform | AU$3.68M | -0.17 | 1363.47% | ― | 157.02% | 69.43% | |
40 Underperform | AU$14.65M | -1.61 | -1688.04% | ― | 11.45% | 0.69% |
* Healthcare Sector Average
AU:ADR
Adherium Ltd.
0.07
-0.12
-64.74%
AU:BMT
Beamtree Holdings Ltd
0.08
-0.12
-61.50%
AU:AHE
MedAdvisor Limited
0.01
-0.01
-50.00%
AU:ALC
Alcidion Group Limited
0.11
<0.01
10.00%
AU:ICR
InteliCare Holdings Limited
0.02
>-0.01
-4.76%
AU:PCK
PainChek Ltd
0.07
-0.35
-83.33%
Adherium Ltd. Corporate Events
Adherium Secures Non-Dilutive AUD$700,000 Loan to Support Working Capital
Oct 6, 2026
Adherium Limited, a global provider of connected respiratory medical devices and digital health solutions, has built its Hailie platform to support remote monitoring of respiratory medication use. The system integrates sensors, mobile and desktop ...
Adherium Lodges Updated Corporate Governance Statement with ASX
Sep 30, 2026
Adherium Ltd has lodged its corporate governance statement for the year ended 30 June 2026 with the ASX, confirming that the document is current as at 30 September 2026 and is available via the company’s investor website. The filing, accompa...
Adherium Secures A$4.67m Term Loan from Major Shareholder Trudell
Sep 15, 2026
Adherium Limited, a global player in digital respiratory management and connected inhaler technology, has consolidated its recent funding arrangements from major shareholder Trudell Medical into a single unsecured term loan. The company’s so...
Adherium Boosts U.S. Revenue but Loss Widens on Growth Investments
Aug 31, 2026
Adherium reported a 157% jump in revenue to $2.1 million for the year to 30 June 2026, driven by the successful launch of its remote patient monitoring program in the United States. Despite the revenue surge, the company’s net loss widened t...
UBS Group AG Exits Substantial Holding in Adherium Ltd.
Jul 30, 2026
UBS Group AG and its related entities have notified Adherium Ltd. that they have ceased to be a substantial shareholder in the company as of 28 July 2026. The change reflects a reduction in UBS’s relevant interest in Adherium’s voting ...
Adherium Appoints Interim CEO as It Accelerates Value-Based Respiratory Care
Jul 29, 2026
Adherium has announced that Chief Executive Officer Dawn Bitz will step down for personal reasons after a year marked by significant commercial progress, including building its remote patient monitoring channel and growing recurring Hailie revenue...
Adherium posts record RPM revenue as U.S. value‑based respiratory strategy gains traction
Jul 28, 2026
Adherium reported record recurring remote patient monitoring subscription revenue of A$479,000 for the June quarter, up 39% sequentially, alongside a 79% jump in customer cash receipts to A$408,000 and continued growth in device shipments and acti...
Adherium Flags Risks as It Advances Respiratory Monitoring Strategy
Jul 26, 2026
Adherium Ltd., listed on the ASX as ADR, operates in the medical device and digital health industry, specialising in respiratory monitoring technologies and related services for asthma and COPD. Its solutions aim to combine smarter inhaler monitor...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.